Journal of Clinical Oncology
Articles in this Issue
Performance of a blood-biomarker test for early detection of pancreatic ductal adenocarcinoma (PDAC) across all stages of disease versus a mixed control population.
659 Background: Early detection of pancreatic ductal adenocarcinoma (PDAC) has a significant impact on pancreatic cancer o...
Impact of infusion timing (IT) on survival outcomes across gastrointestinal (GI) malignancies: A multicenter analysis of circadian rhythm (CR) effects on immune checkpoint inhibitor (ICI) activity.
837 Background: A recent randomized trial suggested that CR may influence ICI activity in patients with lung cancer. Howev...
Associations between ECOG performance status (PS) and patient-reported outcomes (PROs) in patients with gastric or gastroesophageal junction (G/CEJC) adenocarcinoma: Results from the RATIONALE-305 trial.
288 Background: PROs provide critical insight into how patients experience disease and treatment, capturing aspects not re...
Precemtabart tocentecan (Precem-TcT, M9140) in patients with mCRC: Efficacy and safety data at the recommended development dose in the PROCEADE-CRC-01 study.
129 Background: Precem-TcT, an anti-CEACAM5 ADC with TOP1i payload (exatecan), has shown promising monotherapy efficacy du...
Examining the role of circulating tumor DNA in gastroesophageal cancers treated with curative intent.
437 Background: Circulating tumor DNA (ctDNA) is an emerging biomarker that, when positive, suggests the presence of viabl...
Regorafenib dose escalation versus fixed dosing in refractory metastatic colorectal cancer: Survival outcomes from a sub-analysis of the ReTrITA study.
136 Background: The ReTrITA study is a large, multicenter retrospective analysis evaluating real-world outcomes of regoraf...
Use of a computational histology artificial intelligence-powered predictive biomarker for chemotherapy selection in advanced pancreatic cancer patients from a multi-institutional cohort including two prospective studies.
764 Background: This study used the previously developed Computational Histology Artificial Intelligence (CHAI) platform t...
Comparative safety profiles of atezolizumab-bevacizumab vs tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A FAERS-based study.
568 Background: Atezolizumab–bevacizumab (Atezo-Bev) has replaced tyrosine kinase inhibitors (TKIs) as the preferred first...
Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610.
14 Background: Immunotherapy for frontline dMMR/MSI-H mCRC is highly effective, however, nearly half of pts treated with p...
Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study.
477 Background: Tumor recurrence is frequent after surgical resection and local ablation in participants (pts) with hepato...
Characterization of DPYD alterations and treatment-related toxicity in a Chilean cohort of cancer patients.
850 Background: Fluoropyrimidines are widely used in the treatment of solid tumors. Severe treatment-related toxicities oc...
Zanzalintinib versus everolimus in patients with previously treated advanced neuroendocrine tumors: The phase 2/3, randomized STELLAR-311 trial.
TPS647 Background: The targeted agents everolimus (a mammalian target of rapamycin [mTOR] inhibitor) as well as sunitinib...
Efficacy of perioperative and neoadjuvant therapies including immunotherapy in resectable gastroesophageal adenocarcinoma (GEA): A network meta-analysis (NMA).
399 Background: The standard of care for resectable GEA adenocarcinomas is perioperative chemotherapy with the FLOT (fluor...
Leveraging early-onset adverse events (AEs) to inform treatment strategies in pan-gastrointestinal (GI) cancer.
842 Background: Few studies have evaluated the role of early-onset adverse events (AEs) on treatment outcomes for patients...
Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage II-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial.
289 Background: In Asia, adjuvant S-1 monotherapy following D2 gastrectomy represents a standard treatment for patients wi...
Impact of codon-level KRAS mutations on response to TAS-102, TAS-102+bevacizumab, or regorafenib in metastatic colorectal cancer.
66 Background: Regorafenib and trifluridine/tipiracil (TAS-102) with or without bevacizumab are frequently used in the man...
Type 2 diabetes and the risk of gastrointestinal cancers in individuals with metabolic dysfunction associated steatotic liver disease.
493 Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), accompanied by type 2 diabetes mellitus,...
Trop-2 expression and the tumor microenvironment in gastric cancer.
446 Background: Trophoblast Cell Surface Antigen 2 (TROP2) is a transmembrane glycoprotein that has emerged as a promising...
Neoadjuvant short-course radiotherapy combined with CAPOX and PD-1 inhibitor for MSS/pMMR high-risk locally advanced colon cancer: A randomized, prospective, multicentre, phase II trial (TORCH-C).
147 Background: The prognosis for locally advanced colon cancer (LACC) with bulky nodal disease and/or clinically T4 stage...
Three-year and five-year outcomes of a phase II study of perioperative CapeOx therapy for advanced gastric cancer with extensive lymph node metastasis (OGSG1701).
387 Background: The prognosis of advanced gastric cancer (AGC) with para-aortic and/or bulky lymph node metastases remains...
A phase 2 study of vilanterol in combination with a CLDN18.2 bispecific antibody in patients with advanced CLDN18.2-positive pancreatic ductal adenocarcinoma (PDAC).
748 Background: The dense desmoplastic stroma of PDAC, driven by cancer-associated fibroblasts (CAFs), is a major barrier...
Prognostic value of <i>KRAS</i> exon 3, exon 4, and <i>NRAS</i> mutations in pathological stage III colon cancer.
224 Background: The molecular status of RAS , BRAF...
Outcomes of novel tyrosine kinase inhibitors in rare GIST subtypes: A clinico-genomic analysis from the Flatiron Health–Foundation Medicine database.
838 Background: Gastrointestinal stromal tumors (GIST) with KIT or PDGFRA mutations respond well to imatinib, but rare mol...
Prognostic impact of metastatic distribution in microsatellite-stable metastatic colorectal cancer.
55 Background: Immune checkpoint inhibitors (ICIs) have limited efficacy in microsatellite-stable (MSS) metastatic colorec...
Preliminary efficacy and biomarker analysis of CLDN18.2-targeted ADC combined with the NET inhibitor sivelestat in female patients with advanced CLDN18.2-positive pancreatic adenocarcinoma.
718 Background: Estrogen-driven neutrophil extracellular trap (NET) formation has been identified as a key mechanism of re...